Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in Acute Ischemic Stroke
NCT07003386Phase 3Recruiting
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised trial of galantamine in ischemic stroke (2 arms), sponsored by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoint: National Institute of Health Stroke Scale at Day 90. Started Sep 2025; status: recruiting.
02
Drugs
galantamine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07003386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003386.